Varaico: Literature-Extracted Genetic Variants

Gene:RET
Variant:p.L730I
Back to variants list

RET

NM_020975.6:p.L730I

Associated Papers

Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold.

Zhong J et al.

Journal of Medicinal Chemistry, 2025

Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader.

Orsi DL et al.

Rsc Medicinal Chemistry, 2025

ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer.

Lasolle H et al.

Annales D'endocrinologie, 2025

Mechanisms of resistance to RET-directed therapies.

Clifton-Bligh RJ

Endocrine-related Cancer, 2025

Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".

Spitaleri G et al.

Cancers, 2024

Developing Dynamic Structure-Based Pharmacophore and ML-Trained QSAR Models for the Discovery of Novel Resistance-Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis.

Sayyah E et al.

Chemmedchem, 2024

MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.

Saltiki K et al.

European Journal of Endocrinology, 2022

Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.

Ali F et al.

Archives of Pharmacal Research, 2022

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.

Matrone A et al.

Frontiers in Endocrinology, 2022

Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.

Saha D et al.

Journal of Medicinal Chemistry, 2021

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.

Moccia M et al.

Scientific Reports, 2021

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.

Shen T et al.

Npj Precision Oncology, 2021

Drug resistance profiles of mutations in the RET kinase domain.

Liu X et al.

British Journal of Pharmacology, 2018

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."